Mannosylated and histidylated LPR technology for vaccination with tumor antigen mRNA

Methods in Molecular Biology

Volumn 969, Issue , 2013, Pages 247-274

  Pichon, Chantal ^a,b   Midoux, Patrick ^a,b  

^a CENTRE DE BIOPHYSIQUE MOLÉCULAIRE   (France)

^b UNIVERSITÉ D'ORLÉANS   (France)

Author keywords

Dendritic cells; Histidine; Liposomes; MRNA; Polymer; Transfection; Vaccine

Indexed keywords

HISTIDINE; HISTIDYLATED LIPOPOLYPLEXES; LIPOSOME; MANNOSE; MANNOSE RECEPTOR; MANNOSYLATED LIPOPOLYPLEXES; MELANOMA ANTIGEN; MESSENGER RNA; PLASMID DNA; TUMOR ANTIGEN; UNCLASSIFIED DRUG; GLYCOLIPID;

ANIMAL CELL; ARTICLE; CANCER IMMUNIZATION; CELLULAR IMMUNITY; CYTOSOL; DENDRITIC CELL; DNA DETERMINATION; ENDOSOME; FLOW CYTOMETER; GENETIC TRANSFECTION; IMMUNE RESPONSE; IN VITRO STUDY; INTERMETHOD COMPARISON; LIPID ANALYSIS; MELANOMA; MELANOMA B16; MESSENGER RNA SYNTHESIS; MOLECULAR WEIGHT; MOUSE; NONHUMAN; PH; PRIMARY TUMOR; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; PROTON TRANSPORT; RNA ANALYSIS; SPLEEN CELL; SYNTHESIS; TUMOR VOLUME; ULTRAVIOLET SPECTROPHOTOMETRY; ANIMAL; BIOSYNTHESIS; CHEMISTRY; GENETICS; HUMAN; IMMUNOLOGY; METABOLISM; METHODOLOGY; PATHOLOGY; REVIEW; SPLEEN; VACCINATION;

ANIMALS; ANTIGENS, NEOPLASM; DENDRITIC CELLS; GLYCOLIPIDS; HUMANS; IMMUNITY, CELLULAR; LIPOSOMES; MANNOSE; MELANOMA; MICE; RNA, MESSENGER; SPLEEN; TRANSFECTION; VACCINATION;

MLCS; MLOWN;

EID: 84878644143     PISSN: 10643745     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-62703-260-5_16     Document Type: Article

References (35)

1. Hoerr I, Obst R, Rammensee HG et al (2000) In vivo application of RNA leads to induction of speci fic cytotoxic T lymphocytes and antibodies. Eur J Immunol 30:1-7
2. Hess PR, Boczkowski D, Nair SK et al (2006) Vaccination with mRNAs encoding tumorassociated antigens and granulocyte-macrophage colony-stimulating factor ef ficiently primes CTL responses, but is insuf ficient to overcome tolerance to a model tumor/self antigen. Cancer Immunol Immunother 55:672-683
3. Steitz J, Britten CM, Wolfel T et al (2006) Effective induction of anti-melanoma immunity following genetic vaccination with synthetic mRNA coding for the fusion protein EGFP.TRP2. Cancer Immunol Immunother 55:246-253
4. Weide B, Carralot JP, Reese A et al (2008) Results of the first phase I/II clinical vaccination trial with direct injection of mRNA. J Immunother 31:180-188
5. Weide B, Garbe C, Rammensee HG et al (2008) Plasmid DNA-and messenger RNAbased anti-cancer vaccination. Immunol Lett 115:33-42
6. Weide B, Pascolo S, Scheel B et al (2009) Direct injection of protamine-protected mRNA: results of a phase 1/2 vaccination trial in metastatic melanoma patients. J Immunother 32:498-507
7. Rittig SM, Haentschel M, Weimer KJ et al (2011) Intradermal vaccinations with RNA coding for TAA generate CD8+ and CD4+ immune responses and induce clinical bene fit in vaccinated patients. Mol Ther 19:990-999
8. Jackson RJ (1993) Cytoplasmic regulation of mRNA function: the importance of the 3 ¢ untranslated region. Cell 74:9-14
9. Banerjee AK (1980) 5 ¢ -terminal cap structure in eucaryotic messenger ribonucleic acids. Microbiol Rev 44:175-205
10. Sachs AB, Sarnow P, Hentze MW (1997) Starting at the beginning, middle, and end: translation initiation in eukaryotes. Cell 89:831-838
11. Gingras A, Raught B, Sonenberg N (1999) eIF4 initiation factors: effectors of mRNA recruitment to ribosomes and regulators of translation. Annu Rev Biochem 68:913-963
12. Gallie DR (1998) A tale of two termini: a functional interaction between the termini of an mRNA is a prerequisite for ef ficient translation initiation. Gene 216:1-11
13. Scheel B, Teufel R, Probst J et al (2005) Tolllike receptor-dependent activation of several human blood cell types by protamine-condensed mRNA. Eur J Immunol 35:1557-1566
14. Okumura K, Nakase M, Inui M et al (2008) Bax mRNA therapy using cationic liposomes for human malignant melanoma. J Gene Med 10:910-917
15. Mockey M, Bourseau E, Chandrashekhar V et al (2007) mRNA-based cancer vaccine: prevention of B16 melanoma progression and metastasis by systemic injection of MART1 mRNA histidylated lipopolyplexes. Cancer Gene Ther 14:802-814
16. Midoux P, Monsigny M (1999) Ef ficient gene transfer by histidylated polylysine/pDNA complexes. Bioconjug Chem 10:406-411
17. Midoux P, Pichon C, Yaouanc JJ et al (2009) Chemical vectors for gene delivery: a current review on polymers, peptides and lipids containing histidine or imidazole as nucleic acids carriers. Br J Pharmacol 157:166-178
18. Pichon C, Goncalves C, Midoux P (2001) Histidine-rich peptides and polymers for nucleic acids delivery. Adv Drug Deliv Rev 53:75-94
19. Perche F, Benvegnu T, Berchel M et al (2011) Enhancement of dendritic cells transfection in vivo and of vaccination against B16F10 melanoma with mannosylated histidylated lipopolyplexes loaded with tumor antigen messenger RNA. Nanomedicine 7:445-453
20. Perche F, Gosset D, Mével M et al (2010) Selective gene delivery in dendritic cells with mannosylated and histidylated lipopolyplexes. J Drug Target 19(5):315-325
21. Mevel M, Breuzard G, Yaouanc JJ et al (2008) Synthesis and transfection activity of new cationic phosphoramidate lipids: high ef ficiency of an imidazolium derivative. Chembiochem 9:1462-1471
22. Mevel M, Neveu C, Goncalves C et al (2008) Novel neutral imidazole-lipophosphoramides for transfection assays. Chem Commun (Camb) 21:3124-3126
23. Montier T, Delepine P, Benvegnu T et al (2004) Ef ficient gene transfer into human epithelial cell lines using glycosylated cationic carriers and neutral glycosylated co-lipids. Blood Cells Mol Dis 32:271-282
24. Heiser A, Dahm P, Yancey DR et al (2000) Human dendritic cells transfected with RNA encoding prostate-speci fic antigen stimulate prostate-speci fic CTL responses in vitro. J Immunol 164:5508-5514
25. Tuyaerts S, Michiels A, Corthals J et al (2003) Induction of In fl uenza Matrix Protein 1 and MelanA-speci fic T lymphocytes in vitro using mRNA-electroporated dendritic cells. Cancer Gene Ther 10:696-706
26. Shen Z, Reznikoff G, Dranoff G et al (1997) Cloned dendritic cells can present exogenous antigens on both MHC class I and class II molecules. J Immunol 158:2723-2730
27. Monsigny M, Petit C, Roche AC (1988) Colorimetric determination of neutral sugars by a resorcinol sulfuric acid micromethod. Anal Biochem 175:525-530
28. Sluyterman LA (1960) The effect of oxygen upon the micro determination of histidine with the aid of the Pauly reaction. Biochim Biophys Acta 38:218-221
29. Stepinski J, Waddell C, Stolarski R et al (2001) Synthesis and properties of mRNAs containing the novel "anti-reverse" cap analogs 7-methyl(3 ¢ -O-methyl)GpppG and 7-methyl (3 ¢ -deoxy)GpppG. RNA 7:1486-1495
30. Mockey M, Goncalves C, Dupuy FP et al (2006) mRNA transfection of dendritic cells: synergistic effect of ARCA mRNA capping with Poly(A) chains in cis and in trans for a high protein expression level. Biochem Biophys Res Commun 340:1062-1068
31. Grudzien-Nogalska E, Jemielity J, Kowalska J et al (2007) Phosphorothioate cap analogs stabilize mRNA and increase translational ef ficiency in mammalian cells. RNA 13:1745-1755
32. Kuhn AN, Diken M, Kreiter S et al (2010) Phosphorothioate cap analogs increase stability and translational ef ficiency of RNA vaccines in immature dendritic cells and induce superior immune responses in vivo. Gene Ther 17:961-971
33. Serre K, Giraudo L, Siret C et al (2006) CD4 T cell help is required for primary CD8 T cell responses to vesicular antigen delivered to dendritic cells in vivo. Eur J Immunol 36: 1386-1397
34. Fayolle C, Deriaud E, Leclerc C (1991) In vivo induction of cytotoxic T cell response by a free synthetic peptide requires CD4+ T cell help. J Immunol 147:4069-4073
35. Bennett SR, Carbone FR, Karamalis F et al (1997) Induction of a CD8+ cytotoxic T lymphocyte response by cross-priming requires cognate CD4+ T cell help. J Exp Med 186: 65-70